UNH · The Balance Sheet of Care.

02 · The panel — five ways to read the same chart

Five analyst lenses, five answers

The same fundamentals support very different conclusions depending on which framework you trust. Each lens below is a synthesized expert perspective with its own 12-month target.

Recovery / Growth PM

The Convalescent

2025's $16.35 adjusted EPS was the trough, not the new normal. MCR is already falling (−90 bps in Q1), guidance was raised to >$18.25, and the 2027 Medicare Advantage rate increase came in well above the proposal. From here the long-standing 13–16% earnings algorithm resumes — and EPS climbs back above the old $27.66 peak by decade's end.

12-MO TARGET $470 · ~22× FY27 EPS

Value / FCF / Quality

The Cash Counter

~5.4% FCF yield and 0.83× sales for the dominant franchise in its industry. The dividend was raised again and the buyback resumed at a still-depressed multiple. Even if growth stays muted, the cash math protects the downside — a rare quality-plus-value setup once the worst headlines pass.

12-MO TARGET $455 · ~25× FY26 EPS

Regulatory / Disruption Skeptic

The Short Thesis

Two DOJ probes hang over the model: a criminal Medicare-coding case and — more dangerously — an antitrust review of Optum's vertical integration. The margin reset may be structural: adjusted MCR rose 340 bps in 2025 and cost trends (deferred care, GLP-1s) may not fully reverse. At ~22.5× forward, the recovery is priced; Buffett bought the dip and left.

12-MO TARGET $300 · ~17× on de-rating

Moat / Competitive Strategy

The Integrator

Optum — PBM, care delivery, data, and analytics serving 122M+ people — is the real moat: utilization and cost advantages no pure insurer can replicate. That integration is also exactly what the DOJ is probing. Durable advantage, but with a regulatory tax that justifies a discount to the old premium multiple.

12-MO TARGET $440 · fair value + execution credit

Quant / Technical

The Tape Reader

A textbook reversal: fresh 52-week high on a six-firm, two-week upgrade wave, leading a broad managed-care rally. But relative strength has run far and fast — back to ~22× forward, the top of UNH's own historical range versus a ~13× trough a year ago. Momentum positive; valuation percentile rich.

12-MO TARGET $430 · momentum, capped by multiple

03 · Wall Street's read

Wall Street 12-month price targets

A selection of recent, post-Q1 sell-side targets — bars sorted low to high and colored by rating. The dashed line is today's $411. The cluster of fresh Buy targets sits well above the price; the cautious view (Deutsche Bank) sits below.

Consensus mean ≈ $407 (≈ flat) · recent targets cluster $450–$492

BUYHOLDSELL

Recent, post-Q1 2026 targets shown; bars run from a $0 baseline. Six firms raised UNH targets in roughly two weeks (late May–early June 2026), settling in a $450–$492 cluster, while Deutsche Bank (Hold, ~$360) anchors the cautious view. The broader consensus mean (~$407, ≈ flat to the price) is dragged lower by older targets not yet revised up — itself a tell that the Street is mid-revision. Firms, ratings, and targets reflect reported figures as of mid-June 2026 and are illustrative of the spread, not exhaustive.

04 · Price scenarios — 1 / 2 / 3 / 5 years

The prognosis, charted

Synthesized scenario midpoints (mid-year). Returns shown vs. today's $411. These are illustrative frameworks, not forecasts — five-year outcomes hinge on how fast margins normalize and how the DOJ probes resolve.

1 Year

Mid-2027

Bull$490+19%

Base$430+5%

Bear$300−27%

Prob-wtd$413+0%

2 Years

Mid-2028

Bull$575+40%

Base$475+16%

Bear$270−34%

Prob-wtd$449+9%

3 Years

Mid-2029

Bull$675+64%

Base$525+28%

Bear$250−39%

Prob-wtd$494+20%

5 Years

Mid-2031

Bull$900+119%

Base$640+56%

Bear$230−44%

Prob-wtd$603+47%

▸ Bull case — show the assumptions & math

Margins normalize quickly: MCR falls back toward the mid-80s, the 2027 MA rate tailwind plus stabilizing membership lift earnings, Optum re-accelerates, and the DOJ probes resolve cleanly. The market re-rates UNH back to its historical ~22–23× premium; EPS climbs above the old peak by 2028–29.

Adj. EPS ≈ $40 by 2031 × ~22.5× exit multiple → ≈ $900 · 5-yr price CAGR ≈ +17%/yr

▸ Base case — show the assumptions & math

A steady recovery: the 13–16% long-term EPS algorithm resumes off the 2026 base, MCR grinds lower, and the DOJ resolves with a manageable settlement (fine / corporate-integrity terms) — no structural break-up. The multiple settles ~18–19×, a modest regulatory discount to the historical ~21×.

Adj. EPS ≈ $34.5 by 2031 × ~18.5× exit multiple → ≈ $640 · 5-yr price CAGR ≈ +9%/yr

▸ Bear case — show the assumptions & math

The reset proves structural: cost trend stays elevated, MA reimbursement and Medicaid losses persist, membership keeps shrinking, and the DOJ antitrust probe escalates toward an enforcement / structural remedy against Optum. EPS stalls and the multiple de-rates toward the trough.

Adj. EPS roughly flat ~$17 with a ~13–14× distressed multiple → ≈ $230 · 5-yr price CAGR ≈ −11%/yr

05 · Follow the cash

Revenue, capex, free cash flow & debt ($B)

Where the money actually goes. The bull and bear theses both live in the gap between these four bars — especially the free-cash-flow bar that eroded through the crisis and is now turning back up.

Annual revenue, capex, FCF & total debt · 2023 → 2026E

REVENUECAPEXFREE CASH FLOWTOTAL DEBT

The whole story in four bars. Revenue compounded ~12%/yr into 2025 then deliberately dips in 2026E (~$439B) as UNH trades membership for margin. Free cash flow (olive) eroded from ~$26B (2023) toward ~$16B (2025) as the margin reset bit — the bear's "cash is leaking" worry — and is the single bar to watch turn back up in 2026. Capex stays small (~$3.8B). Total debt (slate) is large in absolute terms (~$78B, ~43% debt-to-capital) but roughly four years of free cash flow and trending toward the 40% target. Figures illustrative; 2026E FCF derived from guidance, debt is gross and approximate.

06 · Earnings power

The EPS ladder under the targets ($)

The price targets aren't pulled from the air — each is an EPS estimate times an exit multiple. Here's the earnings ladder the scenarios are built on: the dramatic 2024-peak → 2025-trough collapse, then the base-case climb back.

Adjusted EPS · reported vs. estimated, 2023 → 2031E

REPORTEDESTIMATE (BASE)

Adjusted (non-GAAP) EPS — the clean view; reported GAAP earnings were far lower in 2024–25 on cyberattack, divestiture and restructuring charges. Gray = reported ($27.66 peak in 2024, collapsing to $16.35 in 2025), olive = base-case estimates assuming the 13–16% algorithm resumes off the >$18.25 guided 2026 figure. The base case's ~$34.50 of 2031 adj EPS at a ~18.5× exit multiple ≈ the $640 base-case 5-year target — this is the ladder underneath those prices. Estimates beyond 2026 are illustrative.

07 · Growth scorecard

Read this one differently

Year-over-year, latest reported. Unlike a normal growth scorecard, UNH's top line is being deliberately shrunk — the only growth that matters now is the earnings rebound off the trough.

Year-over-year growth by metric · latest

CORE (2025)RESET / RECOVERY (2026E)

The core lines grew double digits right through the 2025 crisis (revenue +12%, UnitedHealthcare +16%) — demand never broke; margin did. So 2026 is a deliberate step backward on the top line (revenue −2%, ~3M fewer members, clay) to rebuild profitability — and the one growth figure that carries the thesis is the +12% adjusted-EPS recovery off the trough. Whether that earnings rebound is durable is the entire debate. 2026E lines are guidance-based.

08 · The debate

Bull vs. Bear

The whole valuation argument compresses into one disagreement: is 2025 a cyclical trough UNH is climbing out of, or a structural break in the model's earning power?

▲ THE BULL CASE

The margin trough is in. MCR improved 90 bps in Q1 2026 (83.9% vs 84.8%) and management raised FY26 adjusted EPS to >$18.25 — the clearest sign the cost surge has crested.
Earnings recover off a real base. 2025's $16.35 adj EPS was the bottom vs $27.66 in 2024; from here the long-run 13–16% algorithm resumes and EPS reclaims the old peak by decade's end.
A direct policy tailwind. The finalized 2027 Medicare Advantage rate increase came in far above the initial proposal — a boost to the core book and the whole sector.
The cash machine is intact. ~5.4% FCF yield, 0.83× sales, a raised dividend, and a buyback resumed at a still-depressed multiple.
Optum is a genuine moat. Vertical integration across insurance, PBM, care delivery and data (122M+ Optum consumers) drives cost and utilization advantages no pure insurer can match.
Conviction is building. CEO Hemsley bought $25M of stock personally; six firms raised targets in two weeks to a $450–$492 cluster; the FTC insulin case is settling.

▼ THE BEAR CASE

The DOJ antitrust probe is existential. A structural remedy forcing Optum's separation from UnitedHealthcare would dismantle the integrated model — not a fine you pay and move on from.
A second, criminal DOJ probe is open-ended. The Medicare-coding investigation has no clear timeline, and a Senate report alleged UNH "aggressively gamed" Medicare Advantage.
The reset may be structural, not cyclical. Adjusted MCR rose 340 bps to 88.9% in 2025; deferred-care demand, GLP-1 costs and MA funding pressure may not fully reverse.
2026 is a rare revenue-decline year. ~3M fewer members and Medicaid margins projected to deepen toward ~−1.8% — the shrink-to-fix has real costs.
The recovery is largely priced. At ~22.5× forward, UNH is back near its historical premium; the consensus mean (~$407) sits right at the price, and the easy re-rating from $235 is done.
Buffett left. Berkshire bought the dip (~$271) and fully exited (~$394) inside a year — read as a rotation away from regulatory risk.

09 · Risk map

Risk map — likelihood × impact

Where each risk sits over a 3–5 year horizon, not just how big it is. The hot upper-right corner — likely and high-impact — is the cost-trend risk; the genuine tail sits one row down, where the DOJ antitrust case lives.

Low impact

Medium impact

High impact

Likely

Non-US exit / FX friction

Medicaid margin pressure
MA funding & rate drag

Cost trend stays elevated

Possible

Capital-allocation missteps

DOJ criminal coding case
MA membership erosion

Tail

Cyber / operational shock

DOJ antitrust → Optum break-up
MA model dismantled

Cost trend stays elevated

Likely × High

If medical-cost trend keeps outrunning pricing, MCR stalls above the mid-80s and the entire EPS-recovery thesis breaks.

DOJ antitrust → Optum break-up

Tail × High

A forced structural separation of Optum from UnitedHealthcare would dismantle the integrated model the bull case rests on — low odds, existential.

DOJ criminal coding case

Possible × High

A large settlement plus a multi-year integrity agreement caps the multiple even if the fine itself is affordable.

MA membership erosion

Possible × High

Deliberate exits turn into a downward spiral; the scale edge in Medicare Advantage quietly erodes.

Medicaid margin pressure

Likely × Medium

Work-requirement terminations and rate lags push Medicaid margins further negative into 2026.

MA funding & rate drag

Likely × Medium

CMS funding mechanics and IRA Part D changes keep a structural drag on the core insurance book.

MA model dismantled